Effectiveness of Chinese Herbal Medicine as a Complementary Treatment for Neutropenia Prevention and Immunity Modulation During Chemotherapy in Patients With Breast Cancer: Protocol for a Real-World Pragmatic Clinical Trial

• Published in: JMIR research protocols Vol. 13; p. e55662
• Main Authors: Wang, Kai-Hung, Shen, Hsuan-Shu, Chu, Sung-Chao, Wang, Tso-Fu, Lin, Ching-Wei, Huang, Wei-Han, Wu, Yi-Feng, Ho, Ching-Chun, Pang, Cheng-Yoong, Li, Chi-Cheng
• Format: Journal Article
• Language: English
• Published: Canada JMIR Publications 11-03-2024
• Subjects: Blood pressure; Breast cancer; Cancer therapies; Cardiovascular disease; Chemotherapy; Clinical trials; Cytotoxicity; Diarrhea; Herbal medicine; Hospitals; Hypertension; Lymphocytes; Medical prognosis; Medicine; Neutropenia; Neutrophils; Performance evaluation; Protocol; Quality of life; Questionnaires; Sample size; Toxicity; blood cell; immunomodulation; programmed cell death protein 1; herbal; blood cells; real-world study; breast cancer; neutropenia; immune cell profile; immunity; complementary; chemotherapy; neutrophil; complementary treatment for cancer; oncology; herbs; Chinese medicine; bedside to bench study; cancer; PD-1; breast; herb; immunology; immunological
• ISSN: 1929-0748; 1929-0748
• DOI: 10.2196/55662

In recent years, advancements in cancer treatment have enabled cancer cell inhibition, leading to improved patient outcomes. However, the side effects of chemotherapy, especially leukopenia, impact patients' ability to tolerate their treatments and affect their quality of life. Traditional Chinese medicine is thought to provide complementary cancer treatment to improve the quality of life and prolong survival time among patients with cancer.
This study aims to evaluate the effectiveness of Chinese herbal medicine (CHM) as a complementary treatment for neutropenia prevention and immunity modulation during chemotherapy in patients with breast cancer.
We will conduct a real-world pragmatic clinical trial to evaluate the effectiveness of CHM as a supplementary therapy to prevent neutropenia in patients with breast cancer undergoing chemotherapy. Patients will be classified into CHM or non-CHM groups based on whether they received CHM during chemotherapy. Using generalized estimating equations or repeated measures ANOVA, we will assess differences in white blood cell counts, absolute neutrophil counts, immune cells, and programmed cell death protein 1 (PD-1) expression levels between the 2 groups.
This study was approved by the research ethics committee of Hualien Tzu Chi Hospital (IRB 110-168-A). The enrollment process began in September 2021 and will stop in December 2024. A total of 140 patients will be recruited. Data cleaning and analysis are expected to finish in the middle of 2025.
Traditional Chinese medicine is the most commonly used complementary medicine, and it has been reported to significantly alleviate chemotherapy-related side effects. This study's findings may contribute to developing effective interventions targeting chemotherapy-related neutropenia among patients with breast cancer in clinical practice.
International Traditional Medicine Clinical Trial Registry ITMCTR2023000054; https://tinyurl.com/yc353hes.
DERR1-10.2196/55662.